Utility of the Cylex Assay in Cardiac Transplant Recipients

Sachin Gupta, Joshua D. Mitchell, David W. Markham, Pradeep P A Mammen, Parag C. Patel, Patricia A. Kaiser, Peter Stastny, W. Steves Ring, J. Michael DiMaio, Mark H. Drazner

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Although the Cylex immune assay has been proposed as a means of tailoring immunosuppression after organ transplantation, there are limited data regarding its utility in cardiac transplant recipients. Therefore, we sought to determine the utility of the Cylex assay in assessing the risk of infection or rejection in cardiac transplant recipients. Methods: This study is a retrospective review of the clinical course of all adult cardiac transplant recipients who underwent a Cylex assay at UT Southwestern Medical Center between January 2004 and September 2007. Results: One hundred eleven patients were free of significant rejection or infection at the time of the first Cylex assay. Most patients (92%) were >1 year post-transplant. Over the next 157 ± 41 (mean ± SD) days, 2 patients had 3 episodes of rejection requiring therapy and 7 patients had 8 infections requiring therapy. The Cylex responses ranged from 17 to 894 ng/ml. No correlation was observed between the baseline Cylex response and subsequent risk of either infection or rejection within 6 months. Lower white blood cell count and African American ethnicity were correlated with a lower Cylex response. Conclusions: In this study, the Cylex assay had limited utility as an adjunct to routine clinical evaluation in assessing risk of infection or rejection in cardiac transplant recipients.

Original languageEnglish (US)
Pages (from-to)817-822
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume27
Issue number8
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Infection
Organ Transplantation
Leukocyte Count
African Americans
Immunosuppression
Transplant Recipients
Transplants
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Gupta, S., Mitchell, J. D., Markham, D. W., Mammen, P. P. A., Patel, P. C., Kaiser, P. A., ... Drazner, M. H. (2008). Utility of the Cylex Assay in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 27(8), 817-822. https://doi.org/10.1016/j.healun.2008.05.014

Utility of the Cylex Assay in Cardiac Transplant Recipients. / Gupta, Sachin; Mitchell, Joshua D.; Markham, David W.; Mammen, Pradeep P A; Patel, Parag C.; Kaiser, Patricia A.; Stastny, Peter; Ring, W. Steves; DiMaio, J. Michael; Drazner, Mark H.

In: Journal of Heart and Lung Transplantation, Vol. 27, No. 8, 08.2008, p. 817-822.

Research output: Contribution to journalArticle

Gupta, S, Mitchell, JD, Markham, DW, Mammen, PPA, Patel, PC, Kaiser, PA, Stastny, P, Ring, WS, DiMaio, JM & Drazner, MH 2008, 'Utility of the Cylex Assay in Cardiac Transplant Recipients', Journal of Heart and Lung Transplantation, vol. 27, no. 8, pp. 817-822. https://doi.org/10.1016/j.healun.2008.05.014
Gupta S, Mitchell JD, Markham DW, Mammen PPA, Patel PC, Kaiser PA et al. Utility of the Cylex Assay in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation. 2008 Aug;27(8):817-822. https://doi.org/10.1016/j.healun.2008.05.014
Gupta, Sachin ; Mitchell, Joshua D. ; Markham, David W. ; Mammen, Pradeep P A ; Patel, Parag C. ; Kaiser, Patricia A. ; Stastny, Peter ; Ring, W. Steves ; DiMaio, J. Michael ; Drazner, Mark H. / Utility of the Cylex Assay in Cardiac Transplant Recipients. In: Journal of Heart and Lung Transplantation. 2008 ; Vol. 27, No. 8. pp. 817-822.
@article{05882858bc5c48189cdd7db14255193d,
title = "Utility of the Cylex Assay in Cardiac Transplant Recipients",
abstract = "Background: Although the Cylex immune assay has been proposed as a means of tailoring immunosuppression after organ transplantation, there are limited data regarding its utility in cardiac transplant recipients. Therefore, we sought to determine the utility of the Cylex assay in assessing the risk of infection or rejection in cardiac transplant recipients. Methods: This study is a retrospective review of the clinical course of all adult cardiac transplant recipients who underwent a Cylex assay at UT Southwestern Medical Center between January 2004 and September 2007. Results: One hundred eleven patients were free of significant rejection or infection at the time of the first Cylex assay. Most patients (92{\%}) were >1 year post-transplant. Over the next 157 ± 41 (mean ± SD) days, 2 patients had 3 episodes of rejection requiring therapy and 7 patients had 8 infections requiring therapy. The Cylex responses ranged from 17 to 894 ng/ml. No correlation was observed between the baseline Cylex response and subsequent risk of either infection or rejection within 6 months. Lower white blood cell count and African American ethnicity were correlated with a lower Cylex response. Conclusions: In this study, the Cylex assay had limited utility as an adjunct to routine clinical evaluation in assessing risk of infection or rejection in cardiac transplant recipients.",
author = "Sachin Gupta and Mitchell, {Joshua D.} and Markham, {David W.} and Mammen, {Pradeep P A} and Patel, {Parag C.} and Kaiser, {Patricia A.} and Peter Stastny and Ring, {W. Steves} and DiMaio, {J. Michael} and Drazner, {Mark H.}",
year = "2008",
month = "8",
doi = "10.1016/j.healun.2008.05.014",
language = "English (US)",
volume = "27",
pages = "817--822",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Utility of the Cylex Assay in Cardiac Transplant Recipients

AU - Gupta, Sachin

AU - Mitchell, Joshua D.

AU - Markham, David W.

AU - Mammen, Pradeep P A

AU - Patel, Parag C.

AU - Kaiser, Patricia A.

AU - Stastny, Peter

AU - Ring, W. Steves

AU - DiMaio, J. Michael

AU - Drazner, Mark H.

PY - 2008/8

Y1 - 2008/8

N2 - Background: Although the Cylex immune assay has been proposed as a means of tailoring immunosuppression after organ transplantation, there are limited data regarding its utility in cardiac transplant recipients. Therefore, we sought to determine the utility of the Cylex assay in assessing the risk of infection or rejection in cardiac transplant recipients. Methods: This study is a retrospective review of the clinical course of all adult cardiac transplant recipients who underwent a Cylex assay at UT Southwestern Medical Center between January 2004 and September 2007. Results: One hundred eleven patients were free of significant rejection or infection at the time of the first Cylex assay. Most patients (92%) were >1 year post-transplant. Over the next 157 ± 41 (mean ± SD) days, 2 patients had 3 episodes of rejection requiring therapy and 7 patients had 8 infections requiring therapy. The Cylex responses ranged from 17 to 894 ng/ml. No correlation was observed between the baseline Cylex response and subsequent risk of either infection or rejection within 6 months. Lower white blood cell count and African American ethnicity were correlated with a lower Cylex response. Conclusions: In this study, the Cylex assay had limited utility as an adjunct to routine clinical evaluation in assessing risk of infection or rejection in cardiac transplant recipients.

AB - Background: Although the Cylex immune assay has been proposed as a means of tailoring immunosuppression after organ transplantation, there are limited data regarding its utility in cardiac transplant recipients. Therefore, we sought to determine the utility of the Cylex assay in assessing the risk of infection or rejection in cardiac transplant recipients. Methods: This study is a retrospective review of the clinical course of all adult cardiac transplant recipients who underwent a Cylex assay at UT Southwestern Medical Center between January 2004 and September 2007. Results: One hundred eleven patients were free of significant rejection or infection at the time of the first Cylex assay. Most patients (92%) were >1 year post-transplant. Over the next 157 ± 41 (mean ± SD) days, 2 patients had 3 episodes of rejection requiring therapy and 7 patients had 8 infections requiring therapy. The Cylex responses ranged from 17 to 894 ng/ml. No correlation was observed between the baseline Cylex response and subsequent risk of either infection or rejection within 6 months. Lower white blood cell count and African American ethnicity were correlated with a lower Cylex response. Conclusions: In this study, the Cylex assay had limited utility as an adjunct to routine clinical evaluation in assessing risk of infection or rejection in cardiac transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=47649103385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649103385&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2008.05.014

DO - 10.1016/j.healun.2008.05.014

M3 - Article

C2 - 18656792

AN - SCOPUS:47649103385

VL - 27

SP - 817

EP - 822

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 8

ER -